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Introduction: In this phase II study, patients with stage IIIB/IV non–
small-cell lung cancer were randomly assigned (1:1:1) to receive 
LY293111 (200 mg twice daily [200 LY293111] or 600 mg twice 
daily [600 LY293111]) or placebo for 7 days, followed by concur-
rent cisplatin (75 mg/m2; day 1) and gemcitabine (1250 mg/m2; days 
1 and 8), every 21 days.The primary endpoint was progression-free 
survival, (PFS), with 75% power to detect 33% improvement com-
pared with placebo (5 months).
Methods: Of 200 randomized patients, 195 were treated. 
Demographics were well balanced across treatment arms: 65% of 
the patients were men; median age was 62 years; 85% had stage IV 
disease; and patients had an Eastern Cooperative Oncology Group 
performance status of 0 (36%) or 1 (64%). 
Results: The most frequent study drug–related toxicities were nausea, 
vomiting, and fatigue. Response rates were similar across treatment 
arms (200 LY293111: 20%; 600 LY293111: 25%; placebo: 31%). 
Conclusions: Median PFS (95% confidence interval) was not signif-
icantly different across treatment arms (200 LY293111: 4.6 months 
[3.2–5.0]; 600 LY293111: 5.6 months [4.1–6.8]; placebo: 6.0 months 
[5.2–7.5]). LY293111 combined with gemcitabine-cisplatin did not 
increase median PFS compared with placebo plus gemcitabine-cispl-
atin in patients with non–small-cell lung cancer.
Key Words: Cisplatin, Gemcitabine, Chemotherapy, Leukotriene 
receptor agonist, Lung cancer, LY293111, Peroxisome proliferators, 
Activated receptor γ agonist.
(J Thorac Oncol. 2014;9: 126–131)
LY293111 is a biphenyl-substituted diaryl ether carboxylic acid that functions as a leukotriene B4 (LTB4) receptor 
antagonist.1,2 Inhibition of this pathway has been postulated as 
a target in the treatment of cancer.3,4 LY293111 also seems to 
affect the expression of various eicosanoids and is a peroxisome 
proliferator–activated receptor γ (PPAR-γ) agonist, which is 
also a potential target for cancer cell inhibition.5 Chang and 
Szabo6 have demonstrated that PPAR-γ protein is expressed in 
50% of primary non–small-cell lung cancer (NSCLC). When 
they treated NSCLC cell lines that expressed PPAR-γ (at both 
the mRNA and protein level) with known PPAR-γ ligands, it 
induced terminal differentiation and apoptosis. Adipophilin 
and adiponectin are two secreted lipid-associated factors that 
have demonstrated regulation by PPAR-γ agonists.7,8
LY293111 has been studied as a single agent and in com-
bination with cytotoxic chemotherapy agents, including gem-
citabine.9–11 In a phase I study, oral LY293111 was generally well 
tolerated, with a recommended phase II dose of 600 mg orally 
twice daily.11 An additional phase I study of LY293111 in combi-
nation with gemcitabine, given at 1000 mg/m2 for 3 of 4 weeks, 
showed the regimen was well tolerated and established the maxi-
mum tolerated dose of LY293111 as 600 mg orally twice daily.10
We designed and conducted a phase II, randomized, 
double-blind trial comparing the combination of gemcitabine 
plus cisplatin and LY293111 versus the combination of gem-
citabine plus cisplatin and placebo in advanced NSCLC.
MATERIALS AND METHODS
Eligible patients (≥18 years of age) had stage IIIB or 
IV NSCLC, at least one unidimensionally measurable lesion 
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meeting Response Evaluation Criteria in Solid Tumors 1.0,12 
an Eastern Cooperative Oncology Group performance status of 
1 or less, and adequate organ function. Patients receiving prior 
chemotherapy or biological therapy for NSCLC were excluded 
from the study. Patients were randomly assigned to receive 
LY293111 200 mg twice daily (200 LY293111), LY293111 
600 mg twice-daily (600 LY293111), or placebo, followed by 
gemcitabine (1250 mg/m2; days 1 and 8), and cisplatin (75 mg/m2, 
day 1), every 21 days. Patients received a lead-in treatment 
(cycle 1) of single-agent oral 200 mg twice-daily LY293111, 
600 mg twice-daily LY293111, or placebo for 7 days to achieve 
steady-state pharmacokinetics. After the lead-in treatment, 
patients received up to six treatment cycles (21 days).
The protocol was approved by the participating sites’ 
ethics boards. Written informed consent was obtained from 
each patient before enrollment.
Response was evaluated using Response Evaluation 
Criteria in Solid Tumors 1.0. The primary endpoint was progres-
sion-free survival (PFS). Patients receiving at least one dose of 
study drug were included in PFS or overall survival (OS) analyses.
Blood samples were collected to assess steady-state 
trough LY293111 plasma concentrations (pre-dose on day 1 of 
cycles 2 and 3) and peak plasma concentrations of LY293111 
and cisplatin pharmacokinetics (postdose day 1 of cycle 2). 
For biomarker analysis, blood samples were collected before 
LY293111 dosing (on visit 0 or day 1 of cycle 1, and day 1 of 
cycle 2). Levels of adipophilin and adiponectin in plasma were 
monitored to determine whether LY293111 acted as a PPAR-γ 
agonist. Levels of interleukin-6, interleukin-8, and tumor 
necrosis factor α were also analyzed. Human plasma samples 
were analyzed for LY293111 levels by using validated liquid 
chromatography/electrospray ionization mass spectroscopy/
tandem mass spectroscopy methods.
On the basis of label information for gemcitabine in 
combination with cisplatin,13 the median PFS for gemcitabine 
and cisplatin plus placebo was assumed to be approximately 5 
months, with a one-sided significance level of 0.2, 75% power, 
and 33% improvement compared with placebo.
PFS and OS were compared among treatments by using 
pairwise log-rank tests, and event time distributions were 
estimated using the Kaplan–Meier method. Tumor response 
rates were compared among treatments using Pearson’s χ2 
test. Adverse events (AEs) were compared among treatments 
using the Mantel-Haenszel χ2 test. Changes from base-
line in disease-related biomarkers were compared between 
 treatments using the nonparametric Wilcoxon test. Analysis 
was conducted with SAS version 8.2 (SAS Institute Inc., 
Cary, NC).
RESULTS
Patient Characteristics
A total of 203 patients were enrolled in the study; of 
these, 200 were randomly assigned to study treatment (71 to 
200 LY293111 arm, 66 to 600 LY293111 arm, and 63 to pla-
cebo arm), and 195 received therapy. Treatment arms were well 
balanced for prognostic markers (Table 1). The median number 
of cycles per treatment arm was five; the mean number of cycles 
was 5.3 for placebo and 4.8 for each of the LY293111 arms.
Efficacy
Median PFS times (95% confidence intervals [CI]) 
for 200 LY293111, 600 LY293111, and placebo were 4.6 
TABLE 1.  Demographic and Baseline Characteristics by Treatment Arms
LY293111
(200 mg BID)+ Gemcitabine+ Cisplatin
LY293111
(600 mg BID)+ Gemcitabine+ Cisplatin
Placebo+ Gemcitabine+  
Cisplatin
Patients, total (n = 200) 71 66 63
Patients receiving therapy (n = 195) 70 64 61
Age at entry, yrs
  Median 62.4 60.7 60.9
  Range 36.7–81.2 28.5–87.8 27.8–76.6
Origin, n (%)
  White 68 (97) 62 (97) 59 (97)
  African descent 0 2 (3) 0
  East/Southeast Asian 2 (3) 0 2 (3)
Sex, n (%)
  Female 28 (40) 16 (25) 24 (39)
  Male 42 (60) 48 (75) 37 (61)
ECOG PS at entry, n (%)
  0 25 (36) 25 (39) 21 (34)
  1 45 (64) 39 (61) 40 (66)
Disease state at entry, n (%)
  IIIB 14 (20)  9 (14)  7 (11)
  IV 56 (80) 55 (86) 54 (88)
BID, twice daily; ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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(3.2–5.0) months, 5.6 (4.1–6.8) months, and 6.0 (5.2–7.5), 
respectively (Fig. 1A); LY293111 arms were not statisti-
cally superior to placebo (p >0.20). Six-month PFS rates 
(95% CI) were 29% (18%–39%), 47% (35%–59%), and 
50% (37%–62%), respectively. Median OS times (95% 
CI) for 200 LY293111, 600 LY293111, and placebo were 
10.8 (7.6–12.9) months, 10.7 (9.7–16.2) months, and 15.0 
(12.7–19.1) months, respectively (Fig. 1B); the placebo 
arm had statistically superior survival when compared with 
the 200 LY293111 arm. The 6-month survival rates (95% 
CI) for 200 LY293111, 600 LY293111, and placebo were 
70% (59%–81%), 83% (74%–92%), and 87% (78%–95%), 
respectively.
Table 2 summarizes the best tumor response by treat-
ment arms. The difference in overall tumor response among 
treatment arms was not statistically significant (p = 0.34).
Safety
Sixty-three of the 70 patients treated with 200 
LY293111 experienced AEs (grade 3, n = 27; grade 4, 
n = 13); 62 of the 64 patients treated with 600 LY293111 expe-
rienced AEs (grade 3, n = 19; grade 4, n = 6); and 58 of the 
61 patients receiving placebo experienced AEs (grade 3, n = 23; 
grade 4, n = 8).
The most common study drug–related AEs were nau-
sea (200 LY293111, 70.0%; 600 LY293111, 70.3%; placebo, 
77.0%), vomiting (200 LY293111, 45.7%; 600 LY293111, 
56.2%; placebo, 50.8%), and fatigue (200 LY293111, 35.7%; 
600 LY293111, 45.3%; placebo, 60.7%). The incidence of 
diarrhea was higher in 600 LY293111 (78.1%) than in 200 
LY293111 (30.0%) or placebo (23.0%). The incidence of the 
following study drug–related events was statistically signifi-
cantly different among the treatment arms: fatigue, sensory 
A
B
FIGURE 1.  Kaplan–Meier estimates for progres-
sion-free survival (A) and overall survival (B) time by 
treatment group.
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neuropathy, hypomagnesemia, and infection/febrile neutro-
penia (p <0.05). Table 3 summarizes the treatment-related 
Common Terminology Criteria grade 3 to 4 AEs.
Of the 195 treated patients, seven on-study deaths occurred, 
five of which were study-drug related: three because of pulmo-
nary embolism (1 in each arm) and one each because of cardiore-
spiratory arrest (200 LY263111) and pneumonia (placebo).
Pharmacokinetics
Steady-state pharmacokinetics of LY293111 was 
achieved by day 1 of cycle 2 in both LY293111 arms. The 
steady-state level of LY293111 in the 600-dose arm was 
approximately twice the level observed in the 200-dose arm, 
but interindividual variability was high. These data sug-
gest that cisplatin and gemcitabine did not have a substan-
tial effect on the pharmacokinetics of LY293111. No effect 
on the pharmacokinetics of cisplatin was observed for 200 
LY293111 plus gemcitabine and cisplatin. The interindivid-
ual variability was lower for 200 LY293111 (19.8%) than for 
placebo (42.1%).
Biomarker Modulation
The median change from baseline in serum adiponectin 
levels after 7 days of treatment was significantly higher in the 
600 LY293111 than in the placebo arm (p <0.05). Adipophilin 
expression was increased in a dose-dependent but nonstatistically 
significant manner in LY293111 arms versus placebo (Table 4).
DISCUSSION
Although preclinical studies suggest that LY293111, a 
PPAR-γ agonist, may exhibit activity against NSCLC cells 
expressing PPAR-γ, this phase II study demonstrated that low 
and high doses of LY293111 combined with gemcitabine plus 
cisplatin did not produce significant improvement in 6-month 
PFS or OS in patients with NSCLC compared with placebo 
combined with gemcitabine plus cisplatin. A previous phase II 
trial in non-pretreated patients with advanced pancreatic car-
cinoma also failed to show a benefit by combining LY293111 
with gemcitabine.14
Other efficacy measures were also not significantly 
affected by treatment with low and high doses of LY293111 
TABLE 3.  Summary of Treatment-Related CTC v2 Grade 3/4 Adverse Events
Events Grade
LY293111 (200 mg BID)+ 
Gemcitabine+ Cisplatin
LY293111 (600 mg BID)+ 
Gemcitabine+ Cisplatin
Placebo+ Gemcitabine+ 
Cisplatin
(n = 70) (n = 64) (n = 61)
n % n % n %
Nausea 3 4 5.7 5 7.8 5 8.2
Vomiting 3 5 7.1 8 12.5 4 6.6
Fatigue 3 3 4.3 2 3.1 7 11.5
Neutropenia 3 16 22.9 9 14.1 13 21.3
4 9 12.9 4 6.3 5 8.2
Diarrhea 3 3 4.3 8 12.5 1 1.6
Anemia 3 3 4.3 4 6.3 4 6.6
Thrombocytopenia 3 11 15.7 8 12.5 5 8.2
4 1 1.4 1 1.6 1 1.6
ALT 3 1 1.4 0 0 0 0
AST 4 1 1.4 0 0 0 0
Liver dysfunction 3 1 1.4 0 0 0 0
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CTC v2, Common Terminology Criteria, version 2.
TABLE 2.  Best Tumor Response by Treatment Arms
Best Responsea
LY293111 (200 mg BID)+ Gemcitabine+ 
Cisplatin (n = 70)
LY293111 (600 mg BID)+ Gemcitabine+ 
Cisplatin (n = 64)
Placebo+ Gemcitabine+  
Cisplatin (n = 61)
Complete response, n (%) 0 (0.0) 1 (1.6) 1 (1.6)
Partial response, n (%) 14 (20.0) 15 (23.4) 18 (29.5)
Overall response, n (%) 14 (20.0) 16 (25.0) 19 (31.1)
Stable disease 33 31 23
Progressive disease 15 13 12
Unknown 0 1 3
Unavailable for consideration 8 3 4
BID, twice daily.
aFor patients with a best response of unknown and not available, insufficient data were available to determine any cycle responses because no follow-up computed tomograms were 
obtained after baseline.
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TABLE 4.  Biomarker Modulation after 1-Week, Lead-In Period of Oral Therapy Only
Biomarker Change from Baselinea 200 mg Twice Daily LY293111 (N = 70) 600 mg Twice Daily LY293111 (N = 64)
Placebo  
(N = 61)
Adiponection (μg/ml) N 40 48 35
Median 1.0 1.0 0.0
IQR 0.0 to 2.0 −0.5 to 2.0 −1.0 to 1.0
p value, LY vs. placebo 0.053 0.034 NA
Adiophilin (ratio) N 17 24 18
Median 0.02 0.13 −0.24
IQR −0.25 to 0.38 −0.30 to 0.90 −0.45 to 0.15
p value, LY vs. placebo 0.138 0.166 NA
Interleukin-6 (pg/ml) N 27 28 22
Median 0.0 1.0 −2.0
IQR −6.0 to 3.0 −3.5 to 6.0 −8.0 to 7.0
p value, LY vs. placebo 0.413 0.199 NA
Interleukin-8 (pg/ml) N 28 19 16
Median −2.5 −5.0 −9.5
IQR −15.0 to 2.5 −29.0 to 4.0 −22.0 to 10.0
p value, LY vs. placebo 0.923 0.693 NA
Tumor necrosis factor α N 20 21 12
Median 0.0 0.0 −0.5
IQR 0.0 to 1.5 −1.0 to 1.0 −1.5 to 0.0
p value, LY vs. placebo 0.116 0.434 NA
IQR, interquartile range (25th percentile–75th percentile); N, total number of randomized patients in the treatment group; n = total number of randomized patients in the treatment 
group having both baseline and postbaseline measures; NA, not applicable; IL, interleukin; IFN, interferon.
aAll p values used two-sided Wilcoxon t approximation.
Other biomarkers (IL-2, IL-4, IL-5, IFN-γ, GM-CSF) not reported if n <10 in at least one treatment arm.
versus placebo. No validated surrogate marker has been iden-
tified for the activity of LY293111.7 An interim analysis of this 
study with biomarker data was previously presented.15 This 
final analysis confirms that, although modulation of serum 
adiponectin levels and adipohilin expression were observed, 
treatment efficacy was not affected.
LY293111 did not significantly affect the safety and tol-
erability of gemcitabine plus cisplatin, except for diarrhea. The 
mechanism of gastrointestinal activity of LY293111 is not well 
understood. The phase I study of single-agent LY293111 pro-
duced significant gastrointestinal activity, with diarrhea being 
dose-limiting and the most common toxicity encountered.12
Gemcitabine and cisplatin did not seem to have any effect 
on the pharmacokinetics of LY293111. In addition, LY293111 
combined with gemcitabine plus cisplatin did not seem to have 
a substantial effectS on the pharmacokinetics of cisplatin.
In summary, these results do not suggest any benefit of 
adding LY293111 to the combination of gemcitabine and cis-
platin in patients with advanced NSCLC. Our findings may 
have implications for other agents as anticancer therapies tar-
geting PPAR-γ that are currently in clinical development.
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